四川医学2024,Vol.45Issue(8) :827-832.DOI:10.16252/j.cnki.issn1004-0501-2024.08.003

无创肝纤维化诊断指标在乙型肝炎伴肝硬化及肝癌进展程度中的意义

Significance of Liver Fibrosis Diagnostic Indexes in Hepatitis B with Cirrhosis and Liver Cancer Progression

徐少华 黄江华 朱琳 杨涛 宋娟 龚丽 郑崛村 谢晓霞
四川医学2024,Vol.45Issue(8) :827-832.DOI:10.16252/j.cnki.issn1004-0501-2024.08.003

无创肝纤维化诊断指标在乙型肝炎伴肝硬化及肝癌进展程度中的意义

Significance of Liver Fibrosis Diagnostic Indexes in Hepatitis B with Cirrhosis and Liver Cancer Progression

徐少华 1黄江华 2朱琳 2杨涛 2宋娟 2龚丽 2郑崛村 3谢晓霞2
扫码查看

作者信息

  • 1. 四川中医药高等专科学校附属三台医院·三台县中医院,四川绵阳 621100;川北医学院附属三台医院·三台县人民医院,四川绵阳 621100
  • 2. 川北医学院附属三台医院·三台县人民医院,四川绵阳 621100
  • 3. 成都医学院,四川成都 610083
  • 折叠

摘要

目的 应用由肝脏影像学、血清肝脏纤维化直接和间接标志物组成的无创肝脏纤维化诊断指标,评价其在乙型肝炎伴肝硬化及肝癌患者诊断中的应用价值,并对肝硬化严重程度进行预测.方法 收集2020年1月至2023年12月在我院进行治疗的乙型肝炎病毒感染者214例,分为乙型肝炎组80例、肝硬化组76例和肝硬化伴肝癌组58例.检测患者无创肝纤维化指标:①肝脏影像学的肝脏硬度值(LSM);②血清肝纤维化直接标志物的Ⅲ型前胶原N端肽(PⅢP)、Ⅳ型胶原(Ⅳ)、层黏连蛋白(LN)、透明质酸(HA)、甘胆酸(CG);③血清肝纤维化间接标志物的血小板比率指数(APRI)、天冬氨酸氨基转移酶与丙氨酸氨基转移酶比值(AST/ALT)、单胺氧化酶(MAO)、α-L-岩藻糖苷酶(AFU)、谷胱甘肽还原酶(GR).分析无创肝纤维化指标在肝硬化、肝癌和肝癌Child-Pugh分级中的诊断价值.结果 在3组的比较中,无创肝纤维化指标差异均有统计学意义(P<0.05),并随着病情的发展而升高.ROC曲线分析提示,LSM、PⅢP、LN、IV、HA、CG、MAO、AFU 指标对于肝硬化诊断效能优于 GR、APRI、AST/ALT 指标;LSM、PⅢP、LN、IV、HA、AFU、APRI、AST/ALT指标对于肝硬化伴肝癌诊断效能优于CG、MAO、GR指标;LSM在肝硬化(AUC=0.862,敏感度78.33%,特异度90.01%)和肝硬化伴肝癌(AUC=0.918,敏感度88.89%,特异度92.07%)中诊断价值高于其他指标.肝硬化伴肝癌患者的LSM、PⅢP、LN、IV、HA、AFU、CG、GR诊断指标随着病情的发展而升高,与Child-Pugh分级呈正相关,差异均有统计学意义(P<0.05).结论 无创肝纤维化诊断指标在评估乙型肝炎引起的肝硬化、肝癌及Child-Pugh分级中的诊断价值存在差异,综合运用对肝硬化程度及进展预测有一定的评估价值.

Abstract

Objective To evaluate application value of non-invasive liver fibrosis diagnostic indicators composed of liver imaging,serum liver fibrosis direct and indirect markers in the diagnosis of patients with hepatitis B accompanied by cirrhosis and liver cancer,and to predict their severity.Methods From January 2020 to December 2023,total 214 patients with hepatitis B vi-rus infection were collected and divided into hepatitis B group(n=80),liver cirrhosis group(n=76)and liver cirrhosis with liver cancer group(n=58).Noninvasive liver fibrosis indexes were detected:①liver stiffness value(LSM)of liver imaging;②serum di-rect markers of liver fibrosis,such as type Ⅲ procollagen N-terminal peptide(PⅢ P),type Ⅳ Collagen(Ⅳ),laminin(LN),hyalu-ronic acid(HA),glycocholic acid(CG);③serum indirect marhers of liver fibrosis,such as platelet ratio index(APRI),aspartate aminotransferase to alanine aminotransferase ratio(AST/ALT),monoamine oxidase(MAO),and α-l-fucosidase(AFU),glutathione reductase(GR).The noninvasive liver fibrosis index was used to analyze the diagnostic value in the Child Pugh grading of liver cir-rhosis and liver cancer.Results In the comparison of 3 groups,differences of noninvasive liver fibrosis indexes were statistically significant(P<0.05),and increased with the development of the disease.ROC curve analysis showed that LSM,P Ⅲ P,LN,IV,HA,CG,MAO,AFU were better than GR,APRI,AST/ALT to diagnose liver cirrhosis.LSM,PⅢP,LN,IV,HA,AFU,APRI,AST/ALT were better than CG,MAO,GR to diagnose liver cirrhosis with liver cancer.The diagnostic value of LSM in liver cirrhosis(AUC=0.862,sensitivity 78.33%,specificity 90.01%)and liver cirrhosis with liver cancer(AUC=0.918,sensitivity 88.89%,specificity 92.07%)was higher than other indicators.Diagnostic indexes of LSM,PⅢP,LN,IV,HA,AFU,CG,GR in patients with liver cirrhosis and liver cancer increased with the development of disease,and were positively correlated with Child Pugh classifica-tion with statistically significant differences(P<0.05).Conclusion There would be differences in the diagnostic value of nonin-vasive liver fibrosis index in evaluating liver cirrhosis,liver cancer caused by hepatitis B and Child-Pugh classification.Comprehen-sive application would have certain evaluation value in predicting the degree and progress of liver cirrhosis.

关键词

肝脏纤维化/乙型肝炎/肝硬化/肝癌/肝硬度

Key words

liver fibrosis/hepatitis B/liver cirrhosis/hepatocellular carcinoma/liver stiffness measurement

引用本文复制引用

基金项目

国家重大慢性疾病相关诊断试剂研发课题(2019F000G501)

四川省绵阳市卫生健康委员会科研课题(202014)

四川省绵阳市卫生健康委员会科研课题(202322)

"十三五"国家重点研发计划(2019YFF0216500)

出版年

2024
四川医学
四川省医学会

四川医学

CSTPCD
影响因子:1.174
ISSN:1004-0501
段落导航相关论文